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The purposeful application of bio com-
patible nanomaterials of low toxicity is a 
relevant problem in modern biotechnology. It 
is assumed that the use of nanoparticles will 
help to solve the problems of early disease 
diagnostics and targeted delivery of drugs 
into tissues and cells, as well as new methods 
of selective therapies. C60 fullerene has a 
prominent position among other potentially 
effective therapeutic agents [1]. It is known 
that C60 molecule normalizes cellular 
metabolism and neural processes, increases 
resistance to stress, exhibits antiviral 
properties, has pronounced anti-inflammatory 
and anti-allergic effects, enhances activity of 
enzymes and regenerative capacity of tissues 
[1]. Finally, C60 fullerene and its derivatives 
can be used for the treatment of cancer [2–4]. 
C60 fullerene can be readily dissolved in 
organic solvents, yet it is practically insoluble 
in water [5]. Poor solubility in water severely 
hampers investigation of physiological and 
pharmacological effects of C60 fullerene. As 
a consequence, a number of C60 fullerene 
derivatives with better solubility in polar 
solvents have been synthesized to date [5–6]. 
Pristine C60 fullerene aqueous solution 
(С60FAS) has been received by transferring 
C60 molecules from toluene to water followed 
by sonication [7–8]. The dark brown solution 
was identified to be a typical colloid system 
containing a single C60 molecule and spherical 
clusters with the diameter of 2–3 nm or more 
(depending on the C60 fullerene concentration 
in water) in a hydrated state [7–9]. 
Due to its nanoscale dimensions, the water-
soluble pristine C60 fullerene can penetrate the 
cell membrane [10]. 
Toxicity is a major concern for the use of 
C60 fullerene-containing drugs for biomedical 
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Effect of pristine C60 fullerene aqueous colloid solution (C60FAS; 1 mg/kg dose) on the dynamics 
of fatigue processes in rat soleus muscle after ischemia-reperfusion injury using the tensiometric 
method was studied. Experiments were conducted during the first 5 h and for 5 days after ischemia. 
The changes in maximal strength of muscle contraction and its level of generation between the 
beginning and end of stimulated irritation after intravenous and intramuscular administration of 
C60FAS unmodified fullerene aqueous colloid solution were analyzed. The pronounced protective 
effect of this drug on the dynamics of skeletal muscle contraction was first determined. Protective 
effect of C60FAS unmodified fullerene aqueous colloid solution relative to changes in the levels of 
muscle contraction strength generation between the beginning and end of stimulated irritation was 
15% in the first 5 h after ischemia and increased to 92% on the 5th day of the experiment. In such 
a case, the intravenous therapeutic administration of C60 fullerene aqueous colloid solution was the 
most optimal: the protective effect was 67% versus 49% under intramuscular administration. 
Thus, the development of biomedical nanotechnology with the application of pristine C60 unmodified 
fullerene as a strong antioxidant opens up new possibilities in prevention and treatment of ischemic 
injury in the skeletal muscles.
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applications since they can have damaged 
effects on human cells and animals [11]. It 
is important to point out that the С60FAS 
used does not display toxic effects towards 
rat erythrocyte and thymocyte cells at 
concentrations below 0.1 mg/ml within 24 h of 
incubation [12, 13]. 
The ability of C60 fullerene and its 
derivatives to inactivate reactive oxygen 
species has been described first by [14]. 
Indeed, C60 molecule is capable of attaching 
34 methyl radicals. Antioxidant efficiency 
of C60 fullerene depends on the number of 
active centers in the molecule and the distance 
between active centers and target atoms. 
C60fullerene can quench superoxide anion and 
hydroxyl radicals in both in vivo and in vitro 
systems [15–17].
The ischemia-reperfusion injury of 
various organs or tissues has a complex 
pathogenesis which includes vascular 
dysfunction, inflammation and edema. 
Herewith, the key role in the pathogenesis of 
ischemia-reperfusion injury to tissues and 
organs belongs to free oxygen radicals. It is 
assumed that different types of antioxidants 
are able to mitigate ischemia-reperfusion 
organs or tissues injury. Thus, [18] estimated 
the protective effect of a water-soluble C60 
fullerene derivative [С60(ONO2)7±2] in the 
isolated ischemic-reperfused rat lung. This 
drug has been shown to possess antioxidant 
properties and be able to furthermore release 
nitric oxide displaying the effects similar to 
those of nitroglycerine. Experimental protocol 
included 10 min of stabilization, 45 min of 
ischemia and 60 min of reperfusion. The lungs 
were ventilated with gas mixture containing 
95% О2 and 5% СО2. Ischemia caused increase 
in pulmonary arterial, lung weight and 
filtration coefficients in controls, but C60 
fullerene derivative limited this increase, and 
this was considered to alleviate the ischemia-
reperfusion lung injury.
In canine model [19], 60 min of small 
intestinal ischemia were followed by 1 h of 
reperfusion. A water-soluble C60 fullerene 
derivative (fullerenol) at a dose of 1 mg/kg 
was administered intravenously 30 min prior 
to ischemia (preventively) and immediately 
after reperfusion (therapeutically). An 
increased amount of both malondialdehyde 
(MDA) and conjugated dienes (CD) was found 
in the intestinal tissue at the 30th and 60th min 
of reperfusion in control experiments. On the 
contrary, the tissue content of glutathione 
decreased after 60 min of reperfusion. 
Fullerenol administration did not alter 
histological picture but caused significant 
decrease in tissue content of MDA and CD and 
furthermore increased glutathione level in 
both preventive and therapeutic protocols.
Yang et al. [20] investigated the influence 
of a water-soluble C60 fullerene derivative 
(hexasulfobutyl[60]fullerene) on the ischemic 
brain injury caused by permanent 24 h 
occlusion of middle cerebral artery (MCA) 
in gerbils. Three groups of animals were 
investigated: controls, and receiving low 
(0.5 mg/kg/day) and high (5.0 mg/kg/day 
intraperitoneally during 2 weeks) dose of 
the aforesaid compound. After 24 h of MCA 
occlusion the infarct size was determined 
with triphenylterazolium chloride staining. 
Prolonged hexasulfobutyl[60]fullerene 
therapy resulted in significant decrease in 
cerebral infarct size (by 42–68% in comparison 
with controls). The authors suggested that 
neuroprotective effects of this drug are 
secondary to its antioxidant properties. 
A water-soluble C60 fullerene derivative 
(carboxyfullerene) was injected 30 min prior 
to ischemia- reperfusion either intravenously 
or intracerebroventricularly [21]. Carboxy-
fullerene did not alter infarct size after 
intravenous administration, which may be due 
to limited permeability of blood-brain barrier 
for this compound. Local administration 
of the above-mentioned drug resulted in 
infarct size restriction, preservation of tissue 
glutathione pools and decreased amount of 
lipid peroxidation products in the ischemic 
brain cortex. 
Despite the large number of studies on the 
interaction of С60 fullerene and its derivatives 
with biological objects in vitro and in vivo, a 
little information about the impact of pristine 
water-soluble C60 fullerene on the functional 
properties of skeletal muscles was reported 
[22]. Furthermore, at present time there is 
no information about the C60 fullerene effect 
on the ischemic injury of skeletal muscle. 
Hence, the aim of this study was to estimate 
the protective effect of С60FAS in ischemia-
reperfusion injury of rat soleus muscle. 
Materials and methods 
A highly stable reproducible C60FAS was 
prepared according to protocol [23]. Briefly, for 
the preparation of C60FAS we used a saturated 
solution of pure C60 fullerene (>99.99% purity) 
in toluene with C60 molecule concentration 
corresponding to maximum solubility about 
2.9 mg/ml, and the equal amount of distilled 
water in an open beaker. The two phases 
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formed were treated in ultrasonic bath. The 
procedure was continued until the toluene had 
completely evaporated and the water phase 
was colored yellow. Filtration of the aqueous 
solution allowed to separate the product from 
undissolved C60 fullerenes. The filter pore size 
during the filtration of aqueous solution was 
smaller than 2 µm (Typ Whatmann 602 h1/2).
The purity of prepared C60FAS samples 
was determined by HPLC and GC/MS 
techniques using standard programs. Insoluble 
C60FAS impurities were determined by ultra-
centrifugation: their amount was identified 
to constitute less than 1 µg/ml. Traces of 
toluene after synthesis could not be detected in 
water by GC/MS analysis. Moreover, 1H NMR 
spectrum (400 MHz) of C60FAS recorded in 
heavy water did not reveal any residual proton 
signals.
The concentration of C60 fullerene in the 
prepared C60FAS sample was determined as 
the concentration of total organic carbon in 
aqueous solution (Analytik Jena TOC Analyser 
multi N/C 3100). In our experiments the 
C60FAS sample with 0.15 mg/ml concentration 
of C60 fullerene was used. The resulting atomic 
force microscopy images clearly indicate the 
presence of both individual C60 fullerenes with 
diameter ~0.7 nm and their aggregates with a 
typical diameter up to 50 nm in water [23]. 
Experiments were performed on 30 male 
Wistar rats under 3 months of 170±5 g weight. 
Administration of C60FAS at a dose of 1 mg/
kg was carried out in two ways: intravenously 
and intramuscularly 2 h prior to the start of 
experiment at 1, 2, 3, 4 and 5th experimental day.
The animals used in this study were treated 
in accordance with international principles of 
the European Convention for the protection of 
vertebrate animals used for experimental and 
other scientific purposes (Strasbourg, 1986).
It is important to know that the dose of 
C60 fullerene applied in our experiments was 
significantly lower than the LD50 value defined 
for C60 fullerene which is equivalent to 600 mg/
kg of body weight for the oral administration 
to mice [16].
Anesthesia of animals was performed by 
intraperitoneal administration of nembutal 
(40 mg/kg). For muscle ischemia the branch 
of the femoral artery of the animal, which 
provides blood supply of experimental 
muscle, was dragged by ligatures. After 2 h 
of ischemia, reperfusion was performed by 
cutting the fixing ligatures. Preparation of 
the experiment also included cannulation (a. 
carotis communis sinistra) for pharmaceuticals 
administration and pressure measurement, 
tracheotomy and laminectomy at the lumbar 
spinal cord level. Rat soleus muscle was freed 
from the surrounding tissues. Its tendon 
portion was transversely cut in the distal part. 
The ventral roots were cut in sites of their exit 
from the spinal cord for modulated stimulation 
of efferents in L7-S1segments.
Variation of muscle contraction was 
measured using hypersensitive strain gauges, 
which measure the change in resistance of 
an array of single-walled carbon nanotubes 
(SWCNTs) by deformation [24, 25]. 
SWCNTs were located at the rear end of the 
micropipette, while its front part was attached 
to the investigated muscle tendon. The 
programmable signal generator of special form 
was used to form the stimulating electrical 
signal with duration of 6 s. 
The muscle contraction strength was 
measured during the first 5 h and at 1, 2, 3, 4 and 
5th experimental day after muscle ischemia.
The study of dynamic properties of muscle 
contraction was performed under conditions of 
muscle activation using modulated stimulation 
of efferents. Five filaments of ventral roots 
cut were fixed on stimulating electrodes and 
a special device was used for cyclic sequence 
distribution of electrical signals to stimulate 
the filaments. The distributed stimulation 
allowed monotonous and uniform muscle 
contraction at low stimulation frequencies of 
individual filaments. Stimulation of efferents 
in L7-S1 segments was performed by electric 
pulses of 2 ms, generated by pulse generator 
controlled through the platinum electrodes. 
The characteristics of stimulated signal were 
programmed and transmitted to generator. 
The external load on the muscle was controlled 
with the help of mechanical stimulators. The 
electromagnetic linear motor was used for 
perturbation load.
The experimental curves obtained 
reflect the change of the studied parameters 
as a percentage of intact muscle control 
parameters, which were considered as 100%.
The statistical analysis of the experimental 
data was performed using a Student t-test (the 
level of significance was Р ≤ 0.05).
Results and discussion 
Ischemic injuries account for more than 
35% of the total number of musculoskeletal 
system pathologies that develop due to 
skeletal muscle trauma [26]. While the 
skeletal muscles are more resistant to ischemia 
than other organs, prolonged ischemia can 
cause significant pathologies, including 
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muscle necrosis and apoptosis. The primary 
aim in the treatment of ischemia is rapid 
restoration of blood flow (reperfusion) to the 
damaged sites. However, reperfusion therapy 
leads to a new pathophysiological process 
called reperfusion injury, which also causes 
significant tissue damage [27]. Ischemia-
reperfusion injury of skeletal muscle caused by 
the acute arterial occlusion is lethal in many 
cases [28]. In addition, ischemia-reperfusion 
injury of skeletal muscle might be one of a 
major cause of post-traumatic pathologies 
after surgical procedures [29, 30]. Rapid 
detection of the extent of ischemic injury is 
crucial for the further therapy, yet there are 
no accurate diagnostic tests to achieve this 
goal at the moment [30]. Ischemia-reperfusion 
pathological processes were found to reduce the 
muscle contraction force to 40% after 1 h of 
ischemia and to 90% after 2 h. Its recovery was 
observed only at the end of the 2nd week after 
ischemia-reperfusion [29]. There is also a high 
correlation between the duration of ischemia 
and viability of a muscle fiber [31]. Even 
considering that different types of skeletal 
muscle fibers are characterized by significant 
metabolic differences, it has no significant 
influence on their susceptibility to ischemia-
reperfusion injury [32]. Experimental data 
indicate that the initial pathological effects 
after prolonged ischemia-reperfusion may 
be incomplete, thereby prolonging ischemic 
condition for several days [33]. These data 
established the basis for the study and analysis 
of the dynamics of fatigue processes occurring 
in the rat soleus muscle on the background of 
ischemia-reperfusion pathology development 
within the first 5 h after reperfusion and 
over the 5 days following it under therapeutic 
administration of С60FAS. 
Fig. 1 shows the curves of rat soleus 
muscle maximum strength change, obtained 
under the influence of stimulating irritation 
with duration of 3 min after 1, 2, 3, 4 and 5 
h following the 2 h long muscle ischemia and 
subsequent reperfusion.
The applied relaxationless stimulation 
allowed to analyze the development of 
fatigue processes within the first hours 
after reperfusion. In control experiments, 
the level of reduction of the maximum 
contractile strength of muscle was from 20% 
to 25%. However, regardless of the method 
of therapeutic administration of С60FAS, its 
protective effect was manifested in reducing 
this index to 10% (Fig. 2).
The most pronounced protective effect 
of С60FAS was manifested at comparing 
changes in the levels of maximum strength 
generation between the beginning and the end 
of stimulating irritation (Fig. 3) (in muscle 
without expressed pathologies this parameter 
is practically zero). In this case С60FAS 
reduced this figure to 5% vs. 20% in control 
regardless of the drug administration route. 
It should be noted that such protective effect 
of С60FAS has a significant therapeutic value 
because it’s manifested within the first hours 
after reperfusion, when the basic physiological 
Fig. 1. The maximum strength (F) generation curves 
of ischemic rat soleus muscle under the influence of 
stimulating irritation with 3 min duration: 
a — ischemic muscle without affecting the drug 
(control); b — intravenous administration of 
C60FAS; c — intramuscular administration of 
C60FAS. 
Here and further: (n = 10; 1 mg/kg); ΔF = F(t1) – 
F(t2), where t1 and t2 is the time of the beginning 
and the end of stimulated irritation, 
correspondingly; 1, 2, 3, 4, and 5 are the hours 
after 2 h of muscle ischemia-reperfusion
a
c
b
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processes take place, what leads to severe 
pathology as a consequence [34]. At the same 
time, in spite of the protective effect of 
С60FAS, under ischemia-reperfusion processes 
a progressive decrease of the strength of 
muscle contraction is observed for 5–6 days, 
after which a slow recovery process takes place 
[35–37].
Pathological processes in muscle after 
reperfusion last several days with progressive 
dynamics. Migration of neutrophils into the 
endomysium and later to perimysium already 
occurs within 24 h after the 2 h long ischemia-
reperfusion. Structural process of regeneration 
starts only at the end of the first week after 
the 2 h long reperfusion. There is functional 
and morphological evidence of ischemic and 
reperfusion injury of muscle tissue even 1 week 
after reperfusion. Meanwhile, the increase of 
ischemia from 1 to 2 h delays regeneration 
processes [29]. Therefore, the next stage of 
the study was to investigate the dynamics 
of muscle contractile process caused by the 
analogous stimuli at the 1, 2, 3, 4 and 5 day 
after 2 h long ischemia-reperfusion (Fig. 4).
 Apparently, the manifestation of 
fatigue processes takes place throughout the 
experiment. Simultaneously, a protective 
effect of С60FAS towards the damaged muscle 
tissue is dramatically manifesed: namely, 
while the reduction of the maximum muscle 
contraction strength at the 5th day of the 
experiment reached over 30% in the control, 
the maximum contractile strength at the 
therapeutic administration of С60FAS was 
increased by 20% and 30% by its intramuscular 
and intravenous administration, respectively, 
which nearly eliminated the pattern of 
pathological disorders of muscle contraction 
caused by ischemia injury (Fig. 5).
The most significant protective effects 
of С60FAS were manifested at comparing the 
changes in the levels of maximum strength 
generation between the beginning and the end 
of stimulating irritation (Fig. 6). The decrease 
rate of this indicator was 63% in the control 
group  (without drug administration) on day 
1 of the experiment and decreased to 92% 
by day 5 of the study. Under intramuscular 
drug administration this reduction was 25% 
and 43%, respectively, while the intravenous 
administration of С60FAS reduced the 
difference of the strength response at the 
beginning and the end of stimulation to 23% 
and 25%, respectively. Thus, intravenous 
administration of the drug is more effective 
with regard to its impact on the development 
of fatigue processes in the damaged muscle.
The aforementioned effects may be 
observed due to the fact that the 2 h long 
ischemia-reperfusion of musculus soleus 
significantly reduces the concentration of ATP 
simultaneously with significantly increasing 
lactate. The ATP depletion at 3 h long 
ischemia is known to constitute approximately 
95%, while glycogen is exhausted by 88% 
[34]. Furthermore, we can assume that a 
large number of macroergic phosphates is 
consumed by a damaged muscle cell to maintain 
hemostasis and, as a result of metabolic 
disorders, leads to increased muscle fatigue. 
At the same time, the data available 
from literature indicate that free radicals 
(e. g., superoxide anion and hydroxyl groups) 
represent a major pathogenic factor in the 
process of ischemia-reperfusion tissue damage. 
It includes the initiation of lipid peroxidation, 
the direct inhibition of mitochondrial 
respiratory chain enzymes, inactivation of the 
Fig. 2. The change in the maximum strength (F) of 
contraction of ischemic rat soleus muscle: 
( ) — ischemic muscle without affecting the drug; 
( ) — intravenous administration of C60FAS;  
( ) — intramuscular administration of C60FAS.
Here and further: *P ≤ 0.05
a
c
b
Fig. 3. The level of change in the maximum 
strength (ΔF) of contraction of ischemic rat soleus 
muscle between the beginning and the end of 
stimulated irritation: 
a —  ischemic muscle without affecting the drug 
(control); 
b — intravenous administration of C60FAS; 
c — intramuscular administration of C60FAS
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glyceraldehyde-3-phosphate dehydrogenase, 
inhibiting ATP-ase activity, the inactivation 
of membrane sodium channels, etc. [38]. 
Superoxide anion radical is produced after 
ischemia at the stage of reperfusion in much 
larger quantities and quickly reacts with NO⋅ 
[39]. The ascorbic acid, which is a recognized 
antioxidant, was shown to have a positive 
effect on the reduction of muscle injury caused 
by ischemia-reperfusion [28]. It is assumed 
that the modified C60 fullerene may be regarded 
as a potent scavenger of free radicals induced 
by ischemia-reperfusion small intestine injury 
[19]. The feasibility of C60 fullerene derivatives 
to reduce ischemia-reperfusion lung injury 
has also been shown [18, 40]. In this regard, 
the protective effect of С60FAS on the fatigue 
processes in ischemically damaged muscle can 
be directly linked to the strong antioxidant 
properties of the pristine C60 fullerene [17]. 
Thus, the above data obtained for the first 
time demonstrate a pronounced protective 
effect of pristine С60 fullerene by the means of 
injection of its colloidal aqueous solution on the 
fatigue processes of muscle soleus contraction 
during its ischemia-reperfusion injury, 
namely: during  the study of the reduction 
level of maximum muscle contraction strength 
within the first 5 h after muscle ischemia 
injury, the protective effect of C60FAS 
constituted 10–15% of the control and did not 
depend on the method of drug administration; 
during the study of changes in the levels of 
maximum strength generation between the 
beginning and the end of the stimulus the 
a
c
b
Fig. 4. The maximum strength (F) generation 
curves of ischemic rat soleus muscle under the 
stimulating irritation with 3 min duration:
a —  ischemic muscle without affecting the drug 
(control); 
b — intramuscular administration of C60FAS; 
c — intravenous administration of C60FAS.
Here and further: 1, 2, 3, 4, 5 are the days after 2 h 
of muscle ischemia-reperfusion
Fig. 5. The change in the maximum strength (F) of 
contraction of ischemic rat soleus muscle: 
( ) —  ischemic muscle without affecting the drug 
(control); 
( ) — intramuscular administration of C60FAS; 
( ) — intravenous administration of C60FAS
a
cb
Fig. 6. The level of change in the maximum 
strength (ΔF) of contraction of ischemic rat soleus 
muscle between the beginning and the end of 
stimulated irritation: 
a —  ischemic muscle without affecting the drug 
(control); 
b — intramuscular administration of C60FAS; 
c — intravenous administration of C60FAS
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protective effect of C60FAS was 15% (relative 
to controls) within the first 5 h after muscle 
ischemia injury and increased to 92% by 
the 5th day of the experiment. In this case, 
intravenous administration of therapeutic 
C60FAS is considered to be the most optimal 
route: its protective effect was 67% versus 
49% under intramuscular administration.
Thus, the development of biomedical 
nanotechnology with the application of pristine 
C60 fullerenes, based on their expressed 
antioxidant properties and the lack of data 
on induced acute and chronic intoxications, 
opens up new possibilities in the prevention 
and treatment of ischemic pathologies.
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З використанням тензометричного методу 
досліджено вплив водного колоїдного розчи-
ну немодифікованого С60-фулерену (1 мг/кг) 
на динаміку втомлювальних процесів у кам-
балоподібному м’язі щура після ішемічно-ре-
перфузійного ушкодження. Експерименти 
проводили упродовж перших 5 год і 5 діб після 
ішемії. Аналізували зміни максимальної сили 
скорочення м’яза та рівня його генерації між 
початком і кінцем стимулювального подраз-
нення тривалістю 3 хв за внутрішньовенного і 
внутрішньом’язового введення водного колоїд-
ного розчину немодифікованого С60-фулерену. 
Вперше виявлено виражений захисний ефект 
препарату на динаміку м’язового скорочення. 
Захисна дія водного колоїдного розчину немо-
дифікованого С60-фулерену за порівняння змін 
у рівнях генерації максимальної сили скоро-
чення скелетного м’яза між початком і кінцем 
стимулювального подразнення становила 15% 
у перші 5 год після ішемії і зростала до 92% на 
5-ту добу експерименту. При цьому внутріш-
ньовенне введення водного розчину фулерену 
було найбільш оптимальним: захисний ефект 
досяг 67% проти 49% за внутрішньом’язового 
введення. Отже, розвиток біомедичних нано-
технологій із застосуванням немодифіковано-
го С60-фулерену як сильного антиоксиданта 
відкриває нові можливості у профілактиці та 
лікуванні ішемічних ушкоджень скелетних 
м’язів.
Ключові слова: С60-фулерен, ішемічно-репер-
фу зійне ушкодження.
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С использованием тензометрического мето-
да исследовано влияние водного коллоидного 
раствора немодифицированного С60-фуллерена 
(1 мг/кг) на динамику усталостных процессов 
в камбаловидной мышце крысы после ишеми-
чески-реперфузионного повреждения. Опыты 
проводили в течение первых 5 ч и 5 сут после 
ишемии. Анализировали изменения макси-
мальной силы сокращения мышцы и уровня 
ее генерации между началом и концом стиму-
лирующего раздражения длительностью 3 мин 
при внутривенном и внутримышечном введе-
нии водного коллоидного раствора немодифи-
цированного С60-фуллерена. Впервые обнару-
жен выраженный защитный эффект препарата 
на динамику мышечного сокращения. Защит-
ное действие водного раствора фуллерена при 
сравнении изменений в уровнях генерации 
максимальной силы сокращения скелетной 
мышцы между началом и концом стимулирую-
щих раздражений составило 15% в первые 5 ч 
после ишемии и увеличилось до 92% к 5-м сут 
эксперимента. При этом внутривенное введе-
ние водного коллоидного раствора немодифи-
цированного С60-фуллерена оказалось наиболее 
оптимальным: защитный эффект составил 67% 
против 49% при внутримышечном введении. 
Таким образом, развитие биомедицинских 
нанотехнологий с применением немодифици-
рованного С60-фуллерена в качестве сильного 
антиоксиданта открывает новые возможности 
в профилактике и лечении ишемических по-
вреждений скелетных мышц.
Ключевые слова: С60-фуллерен, ишемически-
реперфузионное повреждение. 
